Human medicines European public assessment report (EPAR): Fulphila, pegfilgrastim, Date of authorisation: 20/11/2018, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Hulio, adalimumab, Date of authorisation: 17/09/2018, Revision: 19, Status: Authorised

Agenda of the CAT meeting 18-20 February 2026

Human medicines European public assessment report (EPAR): Orladeyo, berotralstat, Date of authorisation: 30/04/2021, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Zemcelpro, allogeneic umbilical cord-derived CD34- cells, non-expanded,dorocubicel, Date of authorisation: 25/08/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Pluvicto, lutetium (177Lu) vipivotide tetraxetan, Date of authorisation: 09/12/2022, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Epysqli, eculizumab, Date of authorisation: 26/05/2023, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Wezenla, ustekinumab, Date of authorisation: 20/06/2024, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, Date of authorisation: 24/07/2024, Revision: 7, Status: Authorised

Vaccine Monitoring Platform: List of EMA-funded studies